• Awiqli® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA1
  • Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these injections from seven to one per week1
  • The Awiqli® approval reflects Novo Nordisk's ongoing efforts to advance healthcare innovation and strengthen support for people living with diabetes